ACADIA Pharmaceuticals Inc.
ACAD
Hisse Senetlerindeki Sıralama
#4510
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Hisse Fiyatı
$19.76
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$3.40B
Değişim (1 gün)
3.32%
Değişim (1 yıl)
-5.66%
Ülke
US
Ticaret ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
ACADIA Pharmaceuticals Inc. (ACAD) için P/S oranı
October 2026 itibarıyla P/S oranı TTM: 2.89
ACADIA Pharmaceuticals Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 2.89'dir. 2023 yılının sonunda şirketin P/S oranı 7.06 idi.
ACADIA Pharmaceuticals Inc. için P/S oranı geçmişi 2000 - 2026 arası
Her yılın sonunda P/S oranı
| Yıl | P/S Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 2.89 | -8.68% |
| 2024 | 3.17 | -55.03% |
| 2023 | 7.06 | 41.88% |
| 2022 | 4.98 | -35.68% |
| 2021 | 7.74 | -59.36% |
| 2020 | 19.04 | 2.52% |
| 2019 | 18.57 | 103.07% |
| 2018 | 9.15 | -69.06% |
| 2017 | 29.56 | -84.67% |
| 2016 | 192.80 | -99.67% |
| 2015 | 58.81K | 128.57% |
| 2014 | 25.73K | 1,275.39% |
| 2013 | 1.87K | 3,498.15% |
| 2012 | 51.99 | 90.69% |
| 2011 | 27.27 | 2,380.70% |
| 2010 | 1.10 | -85.78% |
| 2009 | 7.73 | -63.20% |
| 2008 | 21.01 | -59.28% |
| 2007 | 51.59 | 70.96% |
| 2006 | 30.18 | 52.49% |
| 2005 | 19.79 | 30.01% |
| 2004 | 15.22 | 1,049.01% |
| 2003 | 1.32 | -14.53% |
| 2002 | 1.55 | -28.86% |
| 2001 | 2.18 | 31.07% |
| 2000 | 1.66 | 0.00% |
Benzer şirketler veya rakipler için P/S oranı
| Şirket | P/S Oranı | P/S Oranı Farkı | Ülke |
|---|---|---|---|
| 10.02 | 246.20% |
US
|
|
| 40.55 | 1,300.77% |
US
|
|
| 3.96 | 36.83% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 250.49% |
NL
|
